DNER and neoplasm: Given that most adult trials of pan-BET inhibitors have been challenged by similar issues (narrow therapeutic index, due to thrombocytopenia, modest anti-tumor activity as monotherapy), it was agreed that opening additional trials to study pan-BET inhibitors, other than BMS-986158 and BMS-986378/CC-90010, was not a worthwhile strategy.